Organon, one of the world-leading medical players dedicated to women's health, announced the official launch of its business in China on Tuesday.

At the launch ceremony in Shanghai, where the company's China headquarter is based, the US enterprise said it will develop diverse business areas and adopt innovative collaboration models to cater to Chinese women's unmet health needs and support the Healthy China 2030 Initiative.

The company has more than 60 products across multiple therapeutic areas, including cardiovascular diseases, pains, skin health, respiratory diseases, and hormone.

"China is one of the world's most important markets for the company. We'll strive to promote innovations in research and development as well as collaborations with other businesses and the pan-ecological circle to create our own model covering products, service, and the ecological industrial chain," said Wayne Shi, senior vice-president of Organon and market lead of Organon China.

"We'll bring global experience to China and inspire the world with China's practices to support China women's healthy development in the new era."

In another new development in the field of women's health in Shanghai, the Society of Breast Cancer affiliated with the China Anti-cancer Association on July 10 announced that 20 demonstration centers for breast-conserving surgeries for breast cancer patients will be established at large hospitals within this year.

Wu Jiong, chairman of the society, said that the first batch of demonstration centers will be set up in Shanghai, Beijing, as well as the provinces of Zhejiang, Jiangsu, Fujian, Jiangxi, Anhui, Shanxi and Hebei.

"This is an effort to help more early-stage breast cancer sufferers in the country access high-quality, standardized breast-conserving surgeries, which cater to both their physical and psychological needs," said Wu , who is also vice-president of Fudan University Shanghai Cancer Center.

Experts explained that such surgeries are fairly common in many Western countries, while in China, mastectomy surgeries are still dominant.

"Through this program, we also hope to help more medical institutions construct multi-disciplinary teams and elevate the early screening rate, which form the premise for popularizing such surgeries," said Wang Yongsheng, a vice-chairman of the society and director of the Breast Cancer Center at the Shandong Cancer Hospital.

Official statistics show that new breast cancer cases in China numbered more than 410,000 last year, making it the fourth largest malignant tumor in terms of new incidence figures.